Top 5 Articles of the Week: July 6-11

To stay up to date with the latest dermatology news, sign up to receive our eNewsletters.

1.Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia

Pelage Pharmaceuticals announced encouraging phase 2a results for its investigational hair loss therapy, PP405, marking a potential breakthrough in the treatment of androgenetic alopecia. Unlike traditional treatments that target hormonal causes, PP405 acts directly on hair follicle stem cells to stimulate natural hair regeneration. In the trial, the topical therapy demonstrated a strong safety profile, no systemic absorption, and promising early efficacy—including hair regrowth in previously bald areas. With phase 3 trials planned for 2026, the findings signal a possible shift in the future of hair loss treatment.

2.What’s Shaping the Future of Alopecia Treatment, According to Leading Clinicians

Hair loss took center stage at the 2025 SDPA Summer Dermatology Conference, where leading experts shared practical, evidence-based updates on treating alopecia areata, scarring alopecias, and nonscarring hair loss. From the game-changing role of JAK inhibitors and the diagnostic utility of trichoscopy to the overlooked influence of allergic triggers, sessions delivered actionable insights for today’s dermatology clinicians. In this recap, we break down the top 3 takeaways shaping the future of hair loss management.

3.Beyond the Label: Evaluating Bimekizumab’s Mental Health Profile in Psoriasis Treatment

Psoriasis isn’t just skin deep—it often carries a significant psychological burden. At the center of this complex intersection between dermatology and mental health is bimekizumab, a biologic therapy that’s showing promise well beyond skin clearance. Despite an FDA warning for suicidal ideation and behavior, new data from 9 clinical trials suggest that bimekizumab poses minimal psychiatric risk and may actually improve depressive symptoms. In this clinical deep dive, we explore the mental health implications of biologic therapy in psoriasis and what dermatology providers should know when counseling patients.

4.Challenges and Emerging Therapies in CHE: Insights from Fall Clinical PA/NP 2025

Chronic hand eczema (CHE) continues to pose a major dermatologic challenge due to its complex etiology, substantial patient burden, and absence of FDA-approved therapies for moderate to severe disease. At the 2025 Fall Clinical PA/NP Conference in Orlando, Florida, Andrea Murina, MD, and Linda Stein Gold, MD, led a dedicated session addressing the diagnosis, impact, and emerging treatment strategies for CHE.

5.Why Patients Are Choosing Regenerative Aesthetics Over Quick Fixes

In the second part of her interview, Robin Smith, MD, MBA, a leader in regenerative medicine, discussed the growing demand for non-invasive aesthetic solutions that promote long-term skin health rather than temporary results. According to Smith, today’s patients are moving away from injectables and fillers that offer immediate but artificial effects. Instead, they are seeking functional, regenerative tools that improve skin over time, like Exoceuticals’ exosome-powered products with fast-acting and long-lasting benefits.